A Phase IIa, Randomized, Double Blind, Placebo Controlled, Single Dose, Safety and Pharmacokinetic / Pharmacodynamic Study of INP103 (POD L-dopa) Administered in the Presence of Decarboxylase Inhibitor to L-dopa Responsive Parkinson's Disease Patients.
- O'Brien, Terence (Primary Chief Investigator (PCI))
- Bertram, Kelly (Chief Investigator (CI))
Project: Research